Close Menu

NIST

Having raised $1.5 million in funding since announcing the project at a 2017 AACR meeting, the group anticipates completing the first phase of the project by Q2 2020.  

Investigators concluded that the spiked samples from SeraCare were a robust tool for inter-lab comparisons and discussed some areas of discordance seen in the study.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

The methods address challenges like recall and precision, comparing different representations of variant calls, and stratifying performance by variant type and genome context.

Lasting Mark

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

The technique provides the scientific community with a higher-resolution methodology to determine if a mouse cell line has been correctly identified in research.

The public-private consortium, led by the National Institute of Standards and Technology, recently released four new reference materials.

The material has a similar benefit to graphene, in that it is one-atom thin, but has the benefit that DNA does not stick to it as it translocates through the pore. 

The firm will provide DNA from at least 50 mouse cell lines for use in a PCR-based validation assay.

The partners have signed a three-year R&D agreement under which SeraCare will provide its ctDNA reference materials to NIST for comparison between labs.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.